company background image
VYNT

Vyant Bio NasdaqCM:VYNT Stock Report

Last Price

US$1.32

Market Cap

US$7.8m

7D

0.8%

1Y

-87.1%

Updated

25 Nov, 2022

Data

Company Financials +
VYNT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

VYNT Stock Overview

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders.

Vyant Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vyant Bio
Historical stock prices
Current Share PriceUS$1.32
52 Week HighUS$10.25
52 Week LowUS$1.16
Beta0
1 Month Change-46.84%
3 Month Change-64.53%
1 Year Change-87.06%
3 Year Changen/a
5 Year Changen/a
Change since IPO-94.51%

Recent News & Updates

Vyant Bio GAAP EPS of -$0.20, revenue of $0.17M

Aug 22

Recent updates

We Think Vyant Bio (NASDAQ:VYNT) Can Afford To Drive Business Growth

Aug 17
We Think Vyant Bio (NASDAQ:VYNT) Can Afford To Drive Business Growth

Shareholder Returns

VYNTUS BiotechsUS Market
7D0.8%0.4%1.3%
1Y-87.1%-14.4%-18.5%

Return vs Industry: VYNT underperformed the US Biotechs industry which returned -13.5% over the past year.

Return vs Market: VYNT underperformed the US Market which returned -20.2% over the past year.

Price Volatility

Is VYNT's price volatile compared to industry and market?
VYNT volatility
VYNT Average Weekly Movement11.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: VYNT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: VYNT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a34Jay Robertshttps://www.vyantbio.com

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson’s disease (PD).

Vyant Bio, Inc. Fundamentals Summary

How do Vyant Bio's earnings and revenue compare to its market cap?
VYNT fundamental statistics
Market CapUS$7.80m
Earnings (TTM)-US$16.37m
Revenue (TTM)US$980.00k

8.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VYNT income statement (TTM)
RevenueUS$980.00k
Cost of RevenueUS$1.42m
Gross Profit-US$441.00k
Other ExpensesUS$15.93m
Earnings-US$16.37m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.77
Gross Margin-45.00%
Net Profit Margin-1,670.10%
Debt/Equity Ratio0.4%

How did VYNT perform over the long term?

See historical performance and comparison